Patents by Inventor Alam Jahangir

Alam Jahangir has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20230100975
    Abstract: Compounds and methods for treating diseases mediated by a P2X3 and/or a P2X2/3 receptor antagonist, the methods comprising administering to a subject in need thereof an effective amount of a compound of formula (I): or a pharmaceutically acceptable salt, solvate or prodrug thereof, wherein X is O, D, Y, R1, R2, R3, R4, R5, R6, R7 and R8 are as defined herein.
    Type: Application
    Filed: March 22, 2022
    Publication date: March 30, 2023
    Applicant: Roche Palo Alto LLC
    Inventors: Chris Allen Broka, David Scott Carter, Michael Patrick Dillon, Ronald Charles Hawley, Alam Jahangir, Clara Jeou Jen Lin, Daniel Warren Parish
  • Publication number: 20220071963
    Abstract: Methods of treatment and pharmaceutical formulations configured to treat primary and secondary mitochondrial dysfunction are provided. The methods and treatments use an agonist of AMPK. The agonist activates AMPK to activate ATP-producing pathways and inhibiting ATP-consuming pathways, thus allowing for the alleviation of symptoms associated with mitochondrial dysfunctions.
    Type: Application
    Filed: December 31, 2019
    Publication date: March 10, 2022
    Inventors: Tereza MOORE, Tina M. COWAN, Gregory M. ENNS, Mehrdad SHAMLOO, Michael J. GREEN, Alam JAHANGIR, Rolando E. YANES
  • Patent number: 11173144
    Abstract: Adrenergic receptor modulating compounds and methods of using the same are provided. Also provided are methods of treating a subject for a disease or condition associated with an adrenergic receptor including administering a therapeutically effective amount of the subject compound. Aspects of the disclosure include a method of modulating an inflammatory pathway in a cell, such as the production of TNF-alpha in the cell. The method can include contacting a cell with ?1-selective adrenergic receptor modulating compound to selectively activate a cAMP pathway over a beta-arrestin pathway in the cell. Pharmaceutical compositions and kits which include the subject compounds are provided.
    Type: Grant
    Filed: May 12, 2017
    Date of Patent: November 16, 2021
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Mehrdad Shamloo, Alam Jahangir, Bitna Yi, Andrew Kelley Evans, Michael John Green
  • Publication number: 20210008071
    Abstract: Methods for treating respiratory and gastrointestinal diseases mediated by a P2X3 and/or a P2X2/3 receptor antagonist, the methods comprising administering to a subject in need thereof an effective amount of a compound of formula (I): or a pharmaceutically acceptable salt thereof, wherein D, X, Y, R1, R2, R3, R4, R5, R6, R7 and R8 are as defined herein.
    Type: Application
    Filed: September 25, 2020
    Publication date: January 14, 2021
    Applicant: Roche Palo Alto LLC
    Inventors: Chris Allen BROKA, David Scott CARTER, Michael Patrick DILLON, Anthony P.D.W. FORD, Ronald Charles HAWLEY, Alam JAHANGIR, Amy Geraldine MOORE, Daniel Warren PARISH
  • Publication number: 20210009531
    Abstract: Compounds and methods for treating diseases mediated by a P2X3 and/or a P2X2/3 receptor antagonist, the methods comprising administering to a subject in need thereof an effective amount of a compound of formula (I): or a pharmaceutically acceptable salt, solvate or prodrug thereof, wherein X is O, D, Y, R1, R2, R3, R4, R5, R6, R7 and R8 are as defined herein.
    Type: Application
    Filed: September 25, 2020
    Publication date: January 14, 2021
    Applicant: Roche Palo Alto LLC
    Inventors: CHRIS ALLEN BROKA, DAVID SCOTT CARTER, MICHAEL PATRICK DILLON, RONALD CHARLES HAWLEY, ALAM JAHANGIR, CLARA JEOU JEN LIN, DANIEL WARREN PARISH
  • Publication number: 20200237724
    Abstract: Adrenergic receptor modulating compounds and methods of using the same are provided. Also provided are methods of treating a subject for a disease or condition associated with an adrenergic receptor including administering a therapeutically effective amount of the subject compound. Aspects of the disclosure include a method of modulating an inflammatory pathway in a cell, such as the production of TNF-alpha in the cell. The method can include contacting a cell with ?1-selective adrenergic receptor modulating compound to selectively activate a cAMP pathway over a beta-arrestin pathway in the cell. Pharmaceutical compositions and kits which include the subject compounds are provided.
    Type: Application
    Filed: May 12, 2017
    Publication date: July 30, 2020
    Inventors: Mehrdad Shamloo, Alam Jahangir, Bitna Yi, Andrew Kelley Evans, Michael John Green
  • Publication number: 20200115347
    Abstract: Compounds and methods for treating diseases mediated by a P2X3 and/or a P2X2/3 receptor antagonist, the methods comprising administering to a subject in need thereof an effective amount of a compound of formula (I): or a pharmaceutically acceptable salt, solvate or prodrug thereof, wherein X is O, D, Y, R1, R2, R3, R4, R5, R6, R7 and R8 are as defined herein.
    Type: Application
    Filed: December 11, 2019
    Publication date: April 16, 2020
    Applicant: Roche Palo Alto LLC
    Inventors: Chris Allen Broka, David Scott Carter, Michael Patrick Dillon, Ronald Charles Hawley, Alam Jahangir, Clara Jeou Jen Lin, Daniel Warren Parish
  • Publication number: 20190270713
    Abstract: Compounds and methods for treating diseases mediated by a P2X3 and/or a P2X2/3 receptor antagonist, the methods comprising administering to a subject in need thereof an effective amount of a compound of formula (I): or a pharmaceutically acceptable salt, solvate or prodrug thereof, wherein X is O, D, Y, R1, R2, R3, R4, R5, R6, R1 and R8 are as defined herein.
    Type: Application
    Filed: May 22, 2019
    Publication date: September 5, 2019
    Applicant: Roche Palo Alto LLC
    Inventors: CHRIS ALLEN BROKA, DAVID SCOTT CARTER, MICHAEL PATRICK DILLON, RONALD CHARLES HAWLEY, ALAM JAHANGIR, CLARA JEOU JEN LIN, DANIEL WARREN PARISH
  • Publication number: 20190016688
    Abstract: Compounds and methods for treating diseases mediated by a P2X3 and/or a P2X2/3 receptor antagonist, the methods comprising administering to a subject in need thereof an effective amount of a compound of formula (I): or a pharmaceutically acceptable salt, solvate or prodrug thereof, wherein X is O, D, Y, R1, R2, R3, R4, R5, R6, R7 and R8 are as defined herein.
    Type: Application
    Filed: August 9, 2018
    Publication date: January 17, 2019
    Applicant: Roche Palo Alto LLC
    Inventors: Chris Allen Broka, David Scott Carter, Michael Patrick Dillon, Ronald Charles Hawley, Alam Jahangir, Clara Jeou Jen Lin, Daniel Warren Parish
  • Publication number: 20180311240
    Abstract: Methods for treating respiratory and gastrointestinal diseases mediated by a P2X3 and/or a P2X2/3 receptor antagonist, the methods comprising administering to a subject in need thereof an effective amount of a compound of formula (I): or a pharmaceutically acceptable salt thereof, wherein D, X, Y, R1, R2, R3, R4, R5, R6, R7 and R8 are as defined herein.
    Type: Application
    Filed: July 5, 2018
    Publication date: November 1, 2018
    Applicant: Roche Palo Alto LLC
    Inventors: Chris Allen BROKA, David Scott CARTER, Michael Patrick DILLON, Anthony P.D.W. FORD, Ronald Charles HAWLEY, Alam JAHANGIR, Amy Geraldine MOORE, Daniel Warren PARISH
  • Publication number: 20180141919
    Abstract: Compounds and methods for treating diseases mediated by a P2X3 and/or a P2X2/3 receptor antagonist, the methods comprising administering to a subject in need thereof an effective amount of a compound of formula (I): or a pharmaceutically acceptable salt, solvate or prodrug thereof, wherein X is O, D, Y, R1, R2, R3, R4, R5, R6, R7 and R8 are as defined herein.
    Type: Application
    Filed: December 14, 2017
    Publication date: May 24, 2018
    Applicant: Roche Palo Alto LLC
    Inventors: Chris Allen Broka, David Scott Carter, Michael Patrick Dillon, Ronald Charles Hawley, Alam Jahangir, Clara Jeou Jen Lin, Daniel Warren Parish
  • Publication number: 20170096404
    Abstract: Compounds and methods for treating diseases mediated by a P2X3 and/or a P2X2/3 receptor antagonist, the methods comprising administering to a subject in need thereof an effective amount of a compound of formula (I): or a pharmaceutically acceptable salt, solvate or prodrug thereof, wherein X is O, D, Y, R1, R2, R3, R4, R5, R6, R7 and R8 are as defined herein.
    Type: Application
    Filed: December 19, 2016
    Publication date: April 6, 2017
    Applicant: Roche Palo Alto LLC
    Inventors: Chris Allen Broka, David Scott Carter, Michael Patrick Dillon, Ronald Charles Hawley, Alam Jahangir, Clara Jeou Jen Lin, Daniel Warren Parish
  • Patent number: 9556127
    Abstract: Compounds and methods for treating diseases mediated by a P2X3 and/or a P2X2/3 receptor antagonist, the methods comprising administering to a subject in need thereof an effective amount of a compound of formula (I): or a pharmaceutically acceptable salt, solvate or prodrug thereof, wherein D, X, Y, R1, R2, R3, R4, R5, R6, R7 and R8 are as defined herein.
    Type: Grant
    Filed: August 6, 2014
    Date of Patent: January 31, 2017
    Assignee: Roche Palo Alto LLC
    Inventors: Chris Allen Broka, David Scott Carter, Michael Patrick Dillon, Ronald Charles Hawley, Alam Jahangir, Clara Jeou Jen Lin, Daniel Warren Parish
  • Publication number: 20160271131
    Abstract: Methods for treating respiratory and gastrointestinal diseases mediated by a P2X3 and/or a P2X2/3 receptor antagonist, the methods comprising administering to a subject in need thereof an effective amount of a compound of formula (I): or a pharmaceutically acceptable salt thereof, wherein D, X, Y, R1, R2, R3, R4, R5, R6, R7 and R8 are as defined herein.
    Type: Application
    Filed: June 1, 2016
    Publication date: September 22, 2016
    Applicant: Roche Palo Alto LLC
    Inventors: Chris Allen Broka, David Scott Carter, Michael Patrick Dillon, Anthony P.D.W. Ford, Ronald Charles Hawley, Alam Jahangir, Amy Geraldine Moore, Daniel Warren Parish
  • Publication number: 20140357629
    Abstract: Compounds and methods for treating diseases mediated by a P2X3 and/or a P2X2/3 receptor antagonist, the methods comprising administering to a subject in need thereof an effective amount of a compound of formula (I): or a pharmaceutically acceptable salt, solvate or prodrug thereof, wherein D, X, Y, R1, R2, R3, R4, R5, R6, R7 and R8 are as defined herein.
    Type: Application
    Filed: August 6, 2014
    Publication date: December 4, 2014
    Applicant: ROCHE PALO ALTO LLC
    Inventors: Chris Allen Broka, David Scott Carter, Michael Patrick Dillon, Ronald Charles Hawley, Alam Jahangir, Clara Jeou Jen Lin, Daniel Warren Parish
  • Patent number: 8846705
    Abstract: Compounds and methods for treating diseases mediated by a P2X3 and/or a P2X2/3 receptor antagonist, the methods comprising administering to a subject in need thereof an effective amount of a compound of formula (I): or a pharmaceutically acceptable salt, solvate or prodrug thereof, wherein D, X, Y, R1, R2, R3, R4, R5, R6, R7 and R8 are as defined herein.
    Type: Grant
    Filed: December 8, 2010
    Date of Patent: September 30, 2014
    Assignee: Roche Palo Alto LLC
    Inventors: Chris Allen Broka, David Scott Carter, Michael Patrick Dillon, Ronald Charles Hawley, Alam Jahangir, Clara Jeou Jen Lin, Daniel Warren Parish
  • Patent number: 8524725
    Abstract: Methods for treating respiratory and gastrointestinal diseases mediated by a P2X3 and/or a P2X2/3 receptor antagonist, the methods comprising administering to a subject in need thereof an effective amount of a compound of formula (I): or a pharmaceutically acceptable salt thereof, wherein D, X, Y, R1, R2, R3, R4, R5, R6, R7 and R8 are as defined herein.
    Type: Grant
    Filed: July 19, 2011
    Date of Patent: September 3, 2013
    Assignee: Roche Palo Alto LLC
    Inventors: Chris Allen Broka, David Scott Carter, Michael Patrick Dillon, Anthony P. D. W. Ford, Ronald Charles Hawley, Alam Jahangir, Amy Geraldine Moore, Daniel Warren Parish
  • Patent number: 8318764
    Abstract: The present invention relates to the use of novel macrocyclic compounds of Formula I, wherein the variables Q, Q1, Q2, Q3, and Q4 are defined as described herein, which inhibit JAK and are useful for the treatment of auto-immune and inflammatory diseases.
    Type: Grant
    Filed: September 17, 2010
    Date of Patent: November 27, 2012
    Assignee: Roche Palo Alto LLC
    Inventors: Alam Jahangir, Stephen M Lynch, Michael Soth, Hanbiao Yang
  • Patent number: 8227478
    Abstract: Compounds of formula I modulate JNK: wherein X1 and X2 are each simultaneously N or CH; X3 is CH—R2 or N—SO2R, where R is lower alkyl; R1 is aryl or heteroaryl, substituted with 0-3 lower alkyl radicals; R2 is where R3 is H, lower acyl, or an amino acid, or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: December 10, 2009
    Date of Patent: July 24, 2012
    Assignee: Roche Palo Alto LLC
    Inventors: Leyi Gong, Alam Jahangir, Deborah Carol Reuter
  • Patent number: 8183254
    Abstract: The invention relates to prodrugs of JNK inhibitors and corresponding methods, formulations, and compositions for inhibiting JNK and treating JNK-mediated disorders. The application discloses prodrugs of JNK inhibitors, as described below in formula I: wherein m, n, p, q, Q, r, R1, R2, R3, X, X1, X2, X3, X4, X5, Y1, Y2, Z1 and Z2 are as defined herein. The compounds and compositions disclosed herein are useful to modulate the activity of JNK and treat diseases associated with JNK activity. Disclosed are methods and formulations for inhibiting JNK and treating JNK-mediated disorders, and the like, with the compounds, and processes for making said compounds, and corresponding compositions, disclosed herein.
    Type: Grant
    Filed: May 14, 2009
    Date of Patent: May 22, 2012
    Assignee: Roche Palo Alto LLC
    Inventors: Humberto Bartolome Arzeno, James Patrick Dunn, David Michael Goldstein, Leyi Gong, Xiaochun Han, Joan Heather Hogg, Alam Jahangir, Wylie Solang Palmer, Deborah Carol Reuter, Tania Silva, Parcharee Tivitmahaisoon, Teresa Alejandra Trejo-Martin, Shao-Yong Wu